SIGA Technologies Inc.
420 Lexington Avenue
Suite 408
New York,
NY 10170
United States - Map
Phone: 212-672-9100
Fax: 212-697-3130
Web Site: http://www.siga.com
| SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. The company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. The companys product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. The company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force. SIGA Technologies was founded in 1995 and is headquartered in New York, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Eric A. Rose M.D., 57
Exec. Chairman, Chief Exec. Officer and Member of National Biodefense Science Board |
$
400.00K | N/A | Mrs. Ayelet Dugary , 41
Chief Financial Officer, Principal Accounting Officer and Sec. |
$
220.00K | N/A | Dr. Dennis E. Hruby Ph.D., 56
Chief Scientific Officer and VP |
N/A
| N/A | Doris McCarthy ,
Director of Admin. |
N/A
| N/A | Ms. Seane Jones ,
VP of Clinical & Regulatory Affairs |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
0.14%
Profile
